The effect of mandatory generic substitution on the safety of alendronate and patients’ adherence

References

• Data on file. Comparative bioavailability of apo-alendronate and Fosamax 40mg tablets under fasting conditions. Apotex Inc Canada, 2005
   Google Scholar
• Pharmacy Information System. Data on file: cost of generic alendronate and proprietary alendronate in the University Malaya Medical Centre, 2009 19 June; version 8.6
   Google Scholar
• Ministry of Health Malaysia. Generic product list for bioequivalence studies. Kuala Lumpur: National Pharmaceutical Control Bureau, 2011
   Google Scholar
• U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Silver Spring, MD 20993: U.S. Department of Health & Human Services; 2012 [cited 2012 17 May]; 32nd: [Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068.htm
   Google Scholar
• Ministry of Health Malaysia. Malaysian guidelines for the conduct of bioavailability and bioequivalence studies. In: National Pharmaceutical Control Bureau, editor. Kuala Lumpur, 2000:8-16
   Google Scholar
• Food and Drug Administration. Therapeutic Equivalence Evaluations Codes. 2012 [updated 2 March 2012; cited 2012 6 March]; 32:[Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068.htm Therapeutic%20Equivalence%20Evaluations%20Codes
   Google Scholar
• Kanis JA, Reginster JY, Kaufman JM, et al. A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int 2012;23:213-21
   PubMed Web of Science ®Google Scholar
• Dansereau RJ, Crail DJ, Perkins AC. In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications. Curr Med Res Opin 2008;24:1137-45
   PubMed Web of Science ®Google Scholar
• Epstein S, Geusens P, Fisher JE, et al. Irritation profiles of alendronate formulations: implications for clinical safety and efficacy. J Applied Res 2005;5:253-65
   Google Scholar
• Office of the Surgeon General. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: Office of the Surgeon General, 2004
   Google Scholar
• Burge R, Dawson-Hughes B, Solomon DH. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Min Res 2007;22:465-7
   PubMed Web of Science ®Google Scholar
• Cranney A, Guyatt G, Griffith L. IX Summary of meta analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-8
   PubMed Web of Science ®Google Scholar
• Weycker D, Macarios D, Edelsberg J, et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporosis Int 2006;17:1645-52
   PubMed Web of Science ®Google Scholar
• Grima DT, Papaioannou A, Airia P, et al. Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study. BMC Musculoskelet Disord 2010;11:68
   PubMed Web of Science ®Google Scholar
• Ringe JD, Moller G. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 2009;30:213-21
   PubMed Web of Science ®Google Scholar
• Halkin H, Dushenat M, Silverman B, et al. Brand versus generic alendronate: gastrointestinal effects measured by resource utilization. Ann Pharmacother 2009;41:29-34
   Web of Science ®Google Scholar
• Lappe J. Nonadherence to osteoporosis medications: a critical problem. Clin Rev Bone Mineral Metab 2006;4:25-32
   Google Scholar
• Siris E, Harris S, Rosen C, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22
   PubMed Web of Science ®Google Scholar
• Sebaldt RJ, Shane LG, Pham B, et al. Long-term effectiveness outcomes of non-compliance and non-persistence with daily regimen bisphoshonate therapy in patients with osteoporosis treated in tertiary specialist care. Osteoporos Int 2004;15(s107):[Abstract P391SA]
   Google Scholar
• Tosteston AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;15:209-16
   Google Scholar
• Eastell R, Garnero P, Vrijens L, et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: The IMPACT study. Calcif Tissue Int 2003;72(408):[Abstract P297]
   Google Scholar
• Ettinger B, Pressman A, Schein J, et al. Alendronate use among 812 women: Prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Managed Care Pharm 1998:488-92
   Google Scholar
• Dupont WD, Plummer WD. PS: Power and sample size calculation. 2004 [updated 12 June; cited 2007 30 June]; Available from: http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize
   Google Scholar
• Adams CP, Brantner VV. MARKETWATCH: Estimating the cost of new drug development: is it really $802 million? Health Affairs 2006;25:420
   PubMed Web of Science ®Google Scholar
• Xiang XD, Sun X, Briceno G, et al. A combinatorial approach to materials discovery. Science 1995;268:1738-40
   PubMed Web of Science ®Google Scholar
• Bailey WE, Arnold AJ, Lyford TD. Recent Hatch-Waxman reform: balancing innovation, competition and affordability. New York: King & Spalding LLP; 2004 [cited 2012 5 March]; Available from: http://www.buildingipvalue.com/05_NA/107_110.htm
   Google Scholar
• Lietzan EK. A brief history of 180-day exclusivity under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act. Food Drug Law J 2004;59:287-323
   PubMed Web of Science ®Google Scholar
• Mossinghoff GJ. Overview of the Hatch-Waxman Act and its impact on the drug development process. Food Drug Law J 1998;54:187-94
   Web of Science ®Google Scholar
• Kibwage IO, Pandjaitan R, Poompanich A, et al. WHO Expert Committee on specifications for pharmaceutical preparations - 36th report. Geneva: World Health Organization, 2002
   Google Scholar
• Bauer DC, Black DM, Ensrud KE, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Int Med 2000;160:517-25
   PubMed Web of Science ®Google Scholar
• Fosamax. Product Information (alendronic acid). 1999
   Google Scholar
• Amir SK, Chan SP, Abdullah BJ, et al. Clinical Practice Guidelines on Management of Osteoporosis (Malaysian). 2nd edn. Kuala Lumpur, 2006
   Google Scholar
• Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment – clinical applications. JAMA 2002;288:2880-3
   PubMed Web of Science ®Google Scholar
• McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions. JAMA 2002;288:2868-79
   PubMed Web of Science ®Google Scholar
• Kamatari M, Koto S, Ozawa N, et al. Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Min Metab 2007;25:302-9
   PubMed Web of Science ®Google Scholar
• Papaioannou A, Ioannidis G, Adachi J, et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporosis Int 2003;14:808-13
   PubMed Web of Science ®Google Scholar
• Bukata SV, Healey JH. Bisphosphonates: a practical guide. Curr Opin Orthop 2004;15:376-7
   Google Scholar